Immuron Limited · ASX:IMC
Immuron — Shareholder Meeting (November 2026)
8 slides from Immuron's shareholder meeting presentation, Nov 18, 2026
Slide 1: AGM Presentation 18 November 2026
11 AGM PRESENTATION 18 NOVEMBER, 2026 NASDAQ: IMRN ASX: IMC Steven Lydeamore - CEO
Slide 2: Safe Harbor Statement
22 2 Certain statements made in this presentation are forward -looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended
Slide 3: Immuron transitioning to commercially focused growth
Immuron is a company transitioning from development-led to commercially focused growth. Revenue trends remain positive, cash is sufficient to support operations, and management is seeking external partners for IMM-529 and Travelan® to unlock value while limiting funding risk. The principal valuation
Slide 4: FY26 Financial Achievements
4 FY26 Financial Achievements Global Sales Revenue $7.7m Up 6% Australian Sales Revenue $5.8m Up 10% United States Sales Revenue $1.8m Up 7% Up 13% in $USD Gross Profit Margin 64.5% 0.9% decline1 Net Profit $(3.8)m $1.4m improvement Cash $9.0m $6.2m2 improvement 1. Gross Profit Margin was slightly l
Slide 5: FY26 Clinical Achievements and Operational Highlights
5 FY26 Clinical Achievements and Operational Highlights FDA approval IMM-529 IND Travelan® n=851 trial completed New U.S. Department of Defense subaward New product launch in Australia A yellow circle with white letters AI t d t t Engaged Pullan Consulting to support partnering IMM-529 Strategic res
Slide 6: Continued strong sales growth
6 Continued strong sales growth Global + FY27 YTD October AUD$3.0 million up 10% on prior year Australia + FY27 YTD October AUD$2.5 million up 16% on prior year North America + FY27 YTD Oct AUD$0.5 million down 11% on prior year + USA FY27 YTD Oct AUD$0.5 million down 19% on prior year + Canada FY27
Slide 7: FY27 Outlook
7 FY27 Outlook Continued Travelan® sales growth Portfolio expansion • Evaluating additional in- licensing opportunities • Developing new products Sales expansion • Planned UK launch • Exploring partnerships to expand sales channels in the United States Partnering update for IMM-529 Continued improve
Slide 8: Contact Information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: IMMURON INVESTOR HUB COMMUNICATION AND CONTENT INCLUDING ANNOUNCEMENTS AND CORPORATE RESEARCH